Table of Contents
ISRN Pharmacology
Volume 2011 (2011), Article ID 430549, 8 pages
http://dx.doi.org/10.5402/2011/430549
Research Article

Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy

1Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-Ku, Niigata City 956-8603, Japan
2Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta 10430, Indonesia
3Department of Pharmacology, Faculty of Medicine and Health Sciences, Syarif Hidayatullah Jakarta, State Islamic University, South Jakarta 15412, Indonesia
4Department of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan

Received 31 January 2011; Accepted 10 March 2011

Academic Editors: M. Brunner and D. K. Miller

Copyright © 2011 Wawaimuli Arozal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Outomuro, D. R. Grana, F. Azzato, and J. Milei, “Adriamycin-induced myocardial toxicity: new solutions for an old problem?” International Journal of Cardiology, vol. 117, no. 1, pp. 6–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Fuster, B. J. Gersh, and E. R. Giuliani, “The natural history of idiopathic dilated cardiomyopathy,” American Journal of Cardiology, vol. 47, no. 3, pp. 525–531, 1981. View at Google Scholar · View at Scopus
  3. H. G. Keizer, H. M. Pinedo, G. J. Schuurhuis, and H. Joenje, “Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity,” Pharmacology and Therapeutics, vol. 47, no. 2, pp. 219–231, 1990. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Billingham, J. W. Mason, M. R. Bristow, and J. R. Daniels, “Anthracycline cardiomyopathy monitored by morphologic changes,” Cancer Treatment Reports, vol. 62, no. 6, pp. 865–872, 1978. View at Google Scholar · View at Scopus
  5. T. Godfraind, “Drug-induced cardionecrosis,” Archives of Toxicology Supplement, vol. 55, no. 7, pp. 1–15, 1984. View at Google Scholar · View at Scopus
  6. E. L. Lushnikova, M. G. Klinnikova, O. P. Molodykh, and L. M. Nepomnyashchikh, “Morphological manifestations of heart remodeling in anthracycline-induced dilated cardiomyopathy,” Bulletin of Experimental Biology and Medicine, vol. 138, no. 6, pp. 607–612, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Menna, E. Salvatorelli, and G. Minotti, “Doxorubicin degradation in cardiomyocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 1, pp. 408–419, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Takemura and H. Fujiwara, “Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management,” Progress in Cardiovascular Diseases, vol. 49, no. 5, pp. 330–352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Packer, M. R. Bristow, J. N. Cohn et al., “The effect of carvedilol on morbidity and mortality in patients with chronic heart failure,” The New England Journal of Medicine, vol. 334, no. 21, pp. 1349–1355, 1996. View at Publisher · View at Google Scholar
  10. M. Flesch, C. Maack, B. Cremers, A. T. Bäumer, M. Südkamp, and M. Böhm, “Effect of β-blockers on free radical-induced cardiac contractile dysfunction,” Circulation, vol. 100, no. 4, pp. 346–353, 1999. View at Google Scholar · View at Scopus
  11. G. Feuerstein, G. L. Liu, T. L. Yue et al., “Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model,” European Journal of Pharmacology, vol. 351, no. 3, pp. 341–350, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Wei, L. T. C. Chow, and J. E. Sanderson, “Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction,” Journal of the American College of Cardiology, vol. 36, no. 1, pp. 276–281, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Arozal, K. Watanabe, P. T. Veeraveedu et al., “Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats,” Toxicology, vol. 274, no. 1–3, pp. 18–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. de Nigris, M. Rienzo, C. Schiano, C. Fiorito, A. Casamassimi, and C. Napoli, “Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart,” European Journal of Cancer, vol. 44, no. 3, pp. 334–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Kalay, E. Basar, I. Ozdogru et al., “Protective effects of carvedilol against anthracycline-induced cardiomyopathy,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2258–2262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Soga, F. A. Kamal, K. Watanabe et al., “Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats,” International Journal of Cardiology, vol. 110, no. 3, pp. 378–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Watanabe, Y. Ohta, M. Nakazawa et al., “Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy,” British Journal of Pharmacology, vol. 130, no. 7, pp. 1489–1495, 2000. View at Google Scholar · View at Scopus
  18. N. Gurusamy, K. Watanabe, M. Ma et al., “Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK,” Biochemical and Biophysical Research Communications, vol. 320, no. 3, pp. 773–780, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. K. Smith, R. I. Krohn, and G. T. Hermanson, “Measurement of protein using bicinchoninic acid,” Analytical Biochemistry, vol. 150, no. 1, pp. 76–85, 1985. View at Google Scholar
  20. J. Gutkowska, M. Nemer, M. J. Sole, J. Drouin, and P. Sirois, “Lung is an important source of atrial natriuretic factor in experimental cardiomyopathy,” Journal of Clinical Investigation, vol. 83, no. 5, pp. 1500–1504, 1989. View at Google Scholar · View at Scopus
  21. M. Silberbach and C. T. Roberts, “Natriuretic peptide signalling: molecular and cellular pathways to growth regulation,” Cellular Signalling, vol. 13, no. 4, pp. 221–231, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Yan, H. E. Huang, Q. I. Z. Tang et al., “Breviscapine protects against cardiac hypertrophy through blocking PKC-α-dependent signaling,” Journal of Cellular Biochemistry, vol. 109, no. 6, pp. 1158–1171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. E. Myers, W. P. McGuire, and R. H. Liss, “Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response,” Science, vol. 197, no. 4299, pp. 165–167, 1977. View at Google Scholar
  24. F. Charron and M. Nemer, “GATA transcription factors and cardiac development,” Seminars in Cell and Developmental Biology, vol. 10, no. 1, pp. 85–91, 1999. View at Google Scholar · View at Scopus
  25. J. D. Molkentin, “The zinc finger-containing transcription factors GATA-4, -5, and -6: ubiquitously expressed regulators of tissue-specific gene expression,” Journal of Biological Chemistry, vol. 275, no. 50, pp. 38949–38952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. Liang, L. J. De Windt, S. A. Witt, T. R. Kimball, B. E. Markham, and J. D. Molkentin, “The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo,” Journal of Biological Chemistry, vol. 276, no. 32, pp. 30245–30253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Kim, AL. G. Ma, K. Kitta et al., “Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis,” Molecular Pharmacology, vol. 63, no. 2, pp. 368–377, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Spallarossa, S. Garibaldi, P. Altieri et al., “Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro,” Journal of Molecular and Cellular Cardiology, vol. 37, no. 4, pp. 837–846, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Popelová, M. Sterba, P. Haková et al., “Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death,” British Journal of Cancer, vol. 101, no. 5, pp. 792–802, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Yu, R. Vazquez, E. V. Khojeini, C. Patel, R. Venkataramani, and D. F. Larson, “IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 297, no. 1, pp. H76–H85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Matsui, N. Jia, H. Okamoto et al., “Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy,” Hypertension, vol. 43, no. 6, pp. 1195–1201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Graf, Y. S. Do, N. Ashizawa et al., “Myocardial osteopontin expression is associated with left ventricular hypertrophy,” Circulation, vol. 96, no. 9, pp. 3063–3071, 1997. View at Google Scholar · View at Scopus
  33. P. Georgiadou, E. K. Iliodromitis, C. Varounis et al., “Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease,” Expert Opinion on Therapeutic Targets, vol. 12, no. 8, pp. 917–920, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Watanabe, T. Takahashi, M. Nakazawa et al., “Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy,” Journal of Nuclear Medicine, vol. 43, no. 4, pp. 531–535, 2002. View at Google Scholar · View at Scopus
  35. S. Nanjo, J. Yamazaki, K. Yoshikawa, T. Ish II, and Y. Togane, “Carvedilol prevents myocardial fibrosis in hamsters,” International Heart Journal, vol. 47, no. 4, pp. 607–616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Khan and R. Sheppard, “Fibrosis in heart disease: understanding the role of transforming growth factor-β in cardiomyopathy, valvular disease and arrhythmia,” Immunology, vol. 118, no. 1, pp. 10–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Li, YU. H. Liao, X. Cheng, H. Ge, H. Guo, and M. Wang, “Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction,” International Journal of Cardiology, vol. 111, no. 2, pp. 247–255, 2006. View at Publisher · View at Google Scholar · View at Scopus